| 产品描述: | WT161 是有效的、选择性的HDAC6抑制剂,对HDAC6、HDAC1和HDAC2的IC50值分别为0.4 nM、8.35 nM和15.4 nM,比对其他HDACs的选择性高100倍以上。WT161可诱导凋亡 |
| 靶点: |
HDAC6(Cell-free assay):0.4 nM; HDAC1(Cell-free assay):8.35 nM; HDAC2(Cell-free assay):15.4 nM;Apoptosis; HDAC |
| 体外研究: |
WT161可选择性地抑制HDAC6并显著地提高乙酰化α-tubulin的水平,对整体赖氨酸乙酰化影响甚小。它能够诱导多发性骨髓瘤细胞中乙酰化tubulin的积累和毒性。WT161单药处理时不诱导ER应激反应、UPR或是ER应激相关的凋亡。在培养的MCL JeKo-1和Z138细胞中,WT-161的处理将增加胞内泛素化蛋白水平。在培养的MCL细胞(套细胞淋巴瘤)中,WT-161可剂量依赖性地耗尽cyclin D1水平。WT-161的处理还可诱导MCL细胞中的ER应激反应--GRP78蛋白水平、磷酸化eIF2α水平升高,促凋亡转录因子CHOP被诱导。WT161可引起MCF7、T47D、BT474和MDA-MB231细胞的凋亡性细胞死亡,EGFR、HER2、ERα及下游信号的表达下降 |
| 体内研究: |
WT161在小鼠中具有较为合理的半衰期(1.4小时)和药物曝露量(Cmax=18 mg/L)。单药给药处理时,耐受性良好。WT161在异种移植瘤小鼠模型中可显著地抑制体内MCF7细胞的生长,下调ERα的表达 |
| 细胞实验: |
Cell lines: MM.1S细胞 Concentrations: 3 µM Incubation Time: 16 h Method: 将MM.1S细胞用BTZ (3 nM)和/或tubacin/WT161 (3 µM)处理16小时,然后PBS洗涤细胞,进行后续实验 |
| 动物实验: |
Animal Models: Female NCr nu/nu mice subcutaneously (sc) implanted with 17β-estradiol-sustained release pellets and inoculated s.c. with 5 × 106 MCF-7 cells suspended in 30% Matrigel Dosages: 80 mg/kg Administration: i.p. |
| 参考文献: |
1. Hideshima T, et al. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. Proc Natl Acad Sci U S A. 2016, 113(46):13162-13167. 2. Rekha Rao, et al. Treatment with Histone Deacetylase 6-Specific Inhibitor WT-161 Disrupts hsp90 Function, Abrogates Aggresome Formation and Sensitizes Human Mantle Cell Lymphoma Cells to Lethal ER Stress Induced by Proteasome Inhibitor Carfilzomib. Blood. 2010, 116:2856. 3. Hideshima T, et al. HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer. Oncotarget. 2017, 8(46):80109-80123. |
| 溶解性: |
Soluble in DMSO、Ethanol |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.181 ml |
10.904 ml |
21.808 ml |
| 5 mM |
0.436 ml |
2.181 ml |
4.362 ml |
| 10 mM |
0.218 ml |
1.09 ml |
2.181 ml |
| 50 mM |
0.044 ml |
0.218 ml |
0.436 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |